{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:26:45Z","timestamp":1790803605006,"version":"4.1.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Wake Forest University School of Medicine, Department of Neurological Surgery"},{"name":"NIH T32 Translational Oncology Training Program"},{"DOI":"10.13039\/100007154","name":"Wake Forest University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007154","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Leptomeningeal disease is a debilitating, late-stage form of metastatic cancer disseminated within the cerebrospinal fluid, subarachnoid space, and leptomeninges, leading to significant neurological morbidity and mortality. As systemic cancer treatments improve, rates of leptomeningeal disease have increased, yet prognosis remains exceedingly poor. A wide range of treatment modalities have been trialed; however, no standard of care has been established. Additionally, many clinical trials exclude patients with leptomeningeal disease, limiting available prospective data. In this review, we discuss the efficacy of immunotherapy for leptomeningeal disease from solid tumors including systemic and intrathecal therapies, as well as combined therapy regimens. Our review indicates a continued deficiency in the current prospective literature and highlights ongoing research regarding the leptomeningeal immune microenvironment, which will be critical in directing future study of leptomeningeal disease treatment. Currently, the efficacy of immunotherapies on leptomeningeal disease appears limited, and further prospective research is needed to draw significant conclusions. However, recent advancement in understanding the leptomeningeal microenvironment points to potential efficacy of novel immunotherapies targeting the innate immune system, and further study is warranted to evaluate the efficacy of these treatments in this subpopulation of patients.<\/jats:p>","DOI":"10.1007\/s10555-024-10235-1","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T08:06:31Z","timestamp":1732867591000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities"],"prefix":"10.1007","volume":"44","author":[{"given":"Eleanor C.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan T","family":"Mott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Tatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kounosuke","family":"Watabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"issue":"4","key":"10235_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4274\/ejbh.galenos.2021.2021-4-10","volume":"17","author":"H Rinehardt","year":"2021","unstructured":"Rinehardt, H., Kassem, M., Morgan, E., Palettas, M., Stephens, J. A., Suresh, A., et al. (2021). Assessment of leptomeningeal carcinomatosis diagnosis, management and outcomes in patients with solid tumors over a decade of experience. European Journal of Breast Health, 17(4), 371\u2013377. https:\/\/doi.org\/10.4274\/ejbh.galenos.2021.2021-4-10","journal-title":"European Journal of Breast Health"},{"issue":"7","key":"10235_CR2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s11910-022-01198-3","volume":"22","author":"A Sharma","year":"2022","unstructured":"Sharma, A., Low, J. T., & Kumthekar, P. (2022). Advances in the diagnosis and treatment of leptomeningeal disease. Current Neurology and Neuroscience Reports, 22(7), 413\u2013425. https:\/\/doi.org\/10.1007\/s11910-022-01198-3","journal-title":"Current Neurology and Neuroscience Reports"},{"issue":"2","key":"10235_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1053\/ctrv.1999.0119","volume":"25","author":"SA Grossman","year":"1999","unstructured":"Grossman, S. A., & Krabak, M. J. (1999). Leptomeningeal carcinomatosis. Cancer Treatment Reviews, 25(2), 103\u2013119. https:\/\/doi.org\/10.1053\/ctrv.1999.0119","journal-title":"Cancer Treatment Reviews"},{"issue":"42","key":"10235_CR4","doi-asserted-by":"publisher","first-page":"73312","DOI":"10.18632\/oncotarget.20272","volume":"8","author":"G Nayar","year":"2017","unstructured":"Nayar, G., Ejikeme, T., Chongsathidkiet, P., Elsamadicy, A. A., Blackwell, K. L., Clarke, J. M., et al. (2017). Leptomeningeal disease: Current diagnostic and therapeutic strategies. Oncotarget, 8(42), 73312\u201373328. https:\/\/doi.org\/10.18632\/oncotarget.20272","journal-title":"Oncotarget"},{"issue":"1","key":"10235_CR5","doi-asserted-by":"publisher","first-page":"5954","DOI":"10.1038\/s41467-021-25859-y","volume":"12","author":"PK Brastianos","year":"2021","unstructured":"Brastianos, P. K., Strickland, M. R., Lee, E. Q., Wang, N., Cohen, J. V., Chukwueke, U., et al. (2021). Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nature Communication, 12(1), 5954. https:\/\/doi.org\/10.1038\/s41467-021-25859-y","journal-title":"Nature Communication"},{"issue":"6","key":"10235_CR6","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1007\/s13311-022-01261-4","volume":"19","author":"JA Wilcox","year":"2022","unstructured":"Wilcox, J. A., Li, M. J., & Boire, A. A. (2022). Leptomeningeal metastases: New opportunities in the modern era. Neurotherapeutics, 19(6), 1782\u20131798. https:\/\/doi.org\/10.1007\/s13311-022-01261-4","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10235_CR7","doi-asserted-by":"publisher","first-page":"5955","DOI":"10.1038\/s41467-021-25860-5","volume":"12","author":"SM Prakadan","year":"2021","unstructured":"Prakadan, S. M., Alvarez-Breckenridge, C. A., Markson, S. C., Kim, A. E., Klein, R. H., Nayyar, N., et al. (2021). Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases. Nature Communication, 12(1), 5955. https:\/\/doi.org\/10.1038\/s41467-021-25860-5","journal-title":"Nature Communication"},{"issue":"9","key":"10235_CR8","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.3390\/cancers12092635","volume":"12","author":"P T\u00e9tu","year":"2020","unstructured":"T\u00e9tu, P., Sirven-Villaros, L., Cuzzubbo, S., Ursu, R., Baroudjian, B., Delyon, J., et al. (2020). Impact of new systemic treatment and radiotherapy in melanoma patients with leptomeningeal metastases. Cancers (Basel), 12(9), 2635. https:\/\/doi.org\/10.3390\/cancers12092635","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10235_CR9","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.molmed.2018.04.003","volume":"24","author":"R Rua","year":"2018","unstructured":"Rua, R., & McGavern, D. B. (2018). Advances in meningeal immunity. Trends in Molecular Medicine, 24(6), 542\u2013559. https:\/\/doi.org\/10.1016\/j.molmed.2018.04.003","journal-title":"Trends in Molecular Medicine"},{"issue":"8","key":"10235_CR10","doi-asserted-by":"publisher","first-page":"101203","DOI":"10.1101\/2023.03.17.533041","volume":"2023","author":"J Remsik","year":"2023","unstructured":"Remsik, J., Tong, X., Kunes, R. Z., Li, M. J., Osman, A., Chabot, K., et al. (2023). Leptomeningeal anti-tumor immunity follows unique signaling principles. bioRxiv, 2023(8), 101203. https:\/\/doi.org\/10.1101\/2023.03.17.533041","journal-title":"bioRxiv"},{"issue":"6","key":"10235_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.885","volume":"12","author":"H Ruan","year":"2022","unstructured":"Ruan, H., Wang, Z., Sun, Z., Wei, J., Zhang, L., Ju, H., et al. (2022). Single-cell RNA sequencing reveals the characteristics of cerebrospinal fluid tumour environment in breast cancer and lung cancer leptomeningeal metastases. Clinical and Translational Medicine, 12(6), e885. https:\/\/doi.org\/10.1002\/ctm2.885","journal-title":"Clinical and Translational Medicine"},{"issue":"4","key":"10235_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3171\/jns.1987.66.4.0519","volume":"66","author":"K Shimizu","year":"1987","unstructured":"Shimizu, K., Okamoto, Y., Miyao, Y., Yamada, M., Ushio, Y., Hayakawa, T., et al. (1987). Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2. Journal of Neurosurgery, 66(4), 519\u2013521.","journal-title":"Journal of Neurosurgery"},{"issue":"4","key":"10235_CR13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/bjc.1990.345","volume":"62","author":"R Moseley","year":"1990","unstructured":"Moseley, R., Davies, A., Richardson, R., Zalutsky, M., Carrell, S., Fabre, J., et al. (1990). Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis. British Journal of Cancer, 62(4), 637\u2013642.","journal-title":"British Journal of Cancer"},{"issue":"5","key":"10235_CR14","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1097\/00006123-199711000-00005","volume":"41","author":"DW Laske","year":"1997","unstructured":"Laske, D. W., Muraszko, K. M., Oldfield, E. H., DeVroom, H. L., Sung, C., Dedrick, R. L., et al. (1997). Intraventricular immunotoxin therapy for leptomeningeal neoplasia. Neurosurgery, 41(5), 1039\u20131051.","journal-title":"Neurosurgery"},{"issue":"3","key":"10235_CR15","first-page":"917s","volume":"7","author":"AR Clemons-Miller","year":"2001","unstructured":"Clemons-Miller, A. R., Chatta, G. S., Hutchins, L., Angtuaco, E. J., Ravaggi, A., Santin, A. D., et al. (2001). Intrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal melanoma. Clinical Cancer Research, 7(3), 917s\u2013924s.","journal-title":"Clinical Cancer Research"},{"key":"10235_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/BF02967482","volume":"8","author":"H Yu","year":"2001","unstructured":"Yu, H., Mitsumori, M., Nagata, Y., Katakura, Y., Kokubo, M., Oya, N., et al. (2001). Meningeal carcinomatosis in patients with breast cancer: Report of 8 patients. Breast Cancer, 8, 74\u201378.","journal-title":"Breast Cancer"},{"key":"10235_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.875974","volume":"9","author":"P Iranzo","year":"2022","unstructured":"Iranzo, P., Callejo, A., Assaf, J. D., Molina, G., Lopez, D. E., Garcia-Illescas, D., et al. (2022). Overview of checkpoint inhibitors mechanism of action: Role of immune-related adverse events and their treatment on progression of underlying cancer. Front in Medicine (Lausanne), 9, 875974. https:\/\/doi.org\/10.3389\/fmed.2022.875974","journal-title":"Front in Medicine (Lausanne)"},{"key":"10235_CR18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejca.2019.05.019","volume":"116","author":"LEL Hendriks","year":"2019","unstructured":"Hendriks, L. E. L., Bootsma, G., Mourlanette, J., Henon, C., Mezquita, L., Ferrara, R., et al. (2019). Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. European Journal of Cancer, 116, 182\u2013189. https:\/\/doi.org\/10.1016\/j.ejca.2019.05.019","journal-title":"European Journal of Cancer"},{"key":"10235_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejca.2021.03.037","volume":"150","author":"MM Zheng","year":"2021","unstructured":"Zheng, M. M., Tu, H. Y., Yang, J. J., Zhang, X. C., Zhou, Q., Xu, C. R., et al. (2021). Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments. European Journal of Cancer, 150, 23\u201330. https:\/\/doi.org\/10.1016\/j.ejca.2021.03.037","journal-title":"European Journal of Cancer"},{"key":"10235_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.lungcan.2017.02.022","volume":"108","author":"M Gion","year":"2017","unstructured":"Gion, M., Remon, J., Caramella, C., Soria, J. C., & Besse, B. (2017). Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient. Lung Cancer, 108, 72\u201374. https:\/\/doi.org\/10.1016\/j.lungcan.2017.02.022","journal-title":"Lung Cancer"},{"issue":"1","key":"10235_CR21","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cllc.2019.07.012","volume":"21","author":"M Bover","year":"2020","unstructured":"Bover, M., Yarza, R., & Docampo, L. I. (2020). Four-year lasting sustained complete response after nivolumab in a patient with non-small-cell lung cancer and confirmed leptomeningeal carcinomatosis: Changing the paradigm. Clinical Lung Cancer, 21(1), e1\u2013e5. https:\/\/doi.org\/10.1016\/j.cllc.2019.07.012","journal-title":"Clinical Lung Cancer"},{"key":"10235_CR22","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3389\/fonc.2019.00819","volume":"9","author":"D Arias Ron","year":"2019","unstructured":"Arias Ron, D., Labandeira, C. M., Areses Manrique, M. C., Sampedro Domarco, P., Abdulkader, I., Garcia-Mata, J., et al. (2019). Dramatic response of leptomeningeal carcinomatosis to nivolumab in PD-L1 highly expressive non-small cell lung cancer: A case report. Front, 9, 819. https:\/\/doi.org\/10.3389\/fonc.2019.00819","journal-title":"Front"},{"key":"10235_CR23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.lungcan.2016.05.031","volume":"98","author":"E Dudnik","year":"2016","unstructured":"Dudnik, E., Yust-Katz, S., Nechushtan, H., Goldstein, D. A., Zer, A., Flex, D., et al. (2016). Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. Lung Cancer, 98, 114\u2013117. https:\/\/doi.org\/10.1016\/j.lungcan.2016.05.031","journal-title":"Lung Cancer"},{"key":"10235_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.cpccr.2022.100209","volume":"9","author":"AYT Vincent","year":"2023","unstructured":"Vincent, A. Y. T., & Peters, G. D. (2023). Durable complete leptomeningeal and intracerebral responses to first-line Pembrolizumab in highly-selected Non-small cell lung cancer patients. Current Problems in Cancer: Case Reports, 9, 7. https:\/\/doi.org\/10.1016\/j.cpccr.2022.100209","journal-title":"Current Problems in Cancer: Case Reports"},{"issue":"1","key":"10235_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100096","volume":"2","author":"J Remon","year":"2021","unstructured":"Remon, J., Castro-Henriques, M., Esteller, L., & Vives, J. (2021). Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a patient with NSCLC having leptomeningeal metastases. JTO Clinical and Research Reports, 2(1), 100096. https:\/\/doi.org\/10.1016\/j.jtocrr.2020.100096","journal-title":"JTO Clinical and Research Reports"},{"key":"10235_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpccr.2020.100033","volume":"2","author":"M Mahoney","year":"2020","unstructured":"Mahoney, M., Holmes, F. A., & Cho, B. (2020). Leptomeningeal metastatic hormone receptor positive, HER2 and PD-L1 negative, breast cancer responds after pembrolizumab added to abemaciclib: A case study. Current Problems in Cancer: Case Reports, 2, 100033.","journal-title":"Current Problems in Cancer: Case Reports"},{"issue":"6","key":"10235_CR27","doi-asserted-by":"publisher","first-page":"NP76","DOI":"10.1177\/0300891620904411","volume":"106","author":"L Bonomi","year":"2020","unstructured":"Bonomi, L., Bettini, A. C., Arnoldi, E., Chirco, A., Ghilardi, L., Manara, O., et al. (2020). Nivolumab efficacy in leptomeningeal metastasis of renal cell carcinoma: A case report. Tumori, 106(6), NP76\u2013NP78. https:\/\/doi.org\/10.1177\/0300891620904411","journal-title":"Tumori"},{"issue":"1","key":"10235_CR28","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/pcmr.12652","volume":"31","author":"M Arasaratnam","year":"2018","unstructured":"Arasaratnam, M., Hong, A., Shivalingam, B., Wheeler, H., Guminksi, A. D., Long, G. V., et al. (2018). Leptomeningeal melanoma\u2014A case series in the era of modern systemic therapy. Pigment Cell and Melanoma Research, 31(1), 120\u2013124. https:\/\/doi.org\/10.1111\/pcmr.12652","journal-title":"Pigment Cell and Melanoma Research"},{"key":"10235_CR29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ejca.2021.02.016","volume":"148","author":"E Chorti","year":"2021","unstructured":"Chorti, E., Kebir, S., Ahmed, M. S., Keyvani, K., Umutlu, L., Kanaki, T., et al. (2021). Leptomeningeal disease from melanoma\u2014Poor prognosis despite new therapeutic modalities. European Journal of Cancer, 148, 395\u2013404. https:\/\/doi.org\/10.1016\/j.ejca.2021.02.016","journal-title":"European Journal of Cancer"},{"issue":"3","key":"10235_CR30","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11060-019-03121-2","volume":"142","author":"SD Ferguson","year":"2019","unstructured":"Ferguson, S. D., Bindal, S., Bassett, R. L., Jr., Haydu, L. E., McCutcheon, I. E., Heimberger, A. B., et al. (2019). Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). Journal of Neuro-Oncology, 142(3), 499\u2013509. https:\/\/doi.org\/10.1007\/s11060-019-03121-2","journal-title":"Journal of Neuro-Oncology"},{"issue":"5","key":"10235_CR31","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/s1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long, G. V., Atkinson, V., Lo, S., Sandhu, S., Guminski, A. D., Brown, M. P., et al. (2018). Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: A multicentre randomised phase 2 study. The Lancet Oncology, 19(5), 672\u2013681. https:\/\/doi.org\/10.1016\/s1470-2045(18)30139-6","journal-title":"The Lancet Oncology"},{"issue":"8","key":"10235_CR32","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41591-020-0918-0","volume":"26","author":"PK Brastianos","year":"2020","unstructured":"Brastianos, P. K., Lee, E. Q., Cohen, J. V., Tolaney, S. M., Lin, N. U., Wang, N., et al. (2020). Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nature Medicine, 26(8), 1280\u20131284. https:\/\/doi.org\/10.1038\/s41591-020-0918-0","journal-title":"Nature Medicine"},{"key":"10235_CR33","doi-asserted-by":"publisher","unstructured":"Naidoo, J., Hu, C., Schrek, K., Connolly, R., Santa-Maria, C., Lipson, E., et al. (2018). Pembrolizumab for patients with leptomeningeal disease from advanced solid tumors. Journal of Clinical and Translational Science, 2(S1), 44\u201345. https:\/\/doi.org\/10.1017\/cts.2018.174","DOI":"10.1017\/cts.2018.174"},{"issue":"9","key":"10235_CR34","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1007\/s00415-012-6488-4","volume":"259","author":"I Bot","year":"2012","unstructured":"Bot, I., Blank, C. U., & Brandsma, D. (2012). Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab. Journal of Neurology, 259(9), 1976\u20131978. https:\/\/doi.org\/10.1007\/s00415-012-6488-4","journal-title":"Journal of Neurology"},{"issue":"11","key":"10235_CR35","doi-asserted-by":"publisher","first-page":"763","DOI":"10.2217\/imt-2019-0004","volume":"12","author":"RC Wu","year":"2020","unstructured":"Wu, R. C., Newman, W., Patanowitz, L., Branstetter, B. F., Amankulor, N., & Tarhini, A. A. (2020). Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient. Immunotherapy, 12(11), 763\u2013769. https:\/\/doi.org\/10.2217\/imt-2019-0004","journal-title":"Immunotherapy"},{"issue":"11","key":"10235_CR36","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2169\/internalmedicine.4232-19","volume":"59","author":"K Nakashima","year":"2020","unstructured":"Nakashima, K., Demura, Y., Oi, M., Tabata, M., Tada, T., Shiozaki, K., et al. (2020). Whole-brain radiation and pembrolizumab treatment for a non-small-cell lung cancer patient with meningeal carcinomatosis lacking driver oncogenes led to a long-term survival. Internal Medicine, 59(11), 1433\u20131435. https:\/\/doi.org\/10.2169\/internalmedicine.4232-19","journal-title":"Internal Medicine"},{"key":"10235_CR37","doi-asserted-by":"publisher","unstructured":"Wang, W. J., Lee, K. D., Lu, L. S., Ting, L. L., & Chiou, J. F. (2021). Treating leptomeningeal metastases from primary hepatic neuroendocrine carcinoma with combined radiotherapy and immunotherapy: A case report. Therapeutic Radiology and Oncology, 5.\u00a0https:\/\/doi.org\/10.21037\/tro-19-103","DOI":"10.21037\/tro-19-103"},{"issue":"3","key":"10235_CR38","doi-asserted-by":"publisher","first-page":"CSN101","DOI":"10.2217\/cns-2023-0005","volume":"12","author":"MJ Webb","year":"2023","unstructured":"Webb, M. J., Breen, W. G., Laack, N. N., Leventakos, K., Campian, J. L., & Sener, U. (2023). Proton craniospinal irradiation with bevacizumab and pembrolizumab for leptomeningeal disease: A case report. CNS Oncology, 12(3), CSN101. https:\/\/doi.org\/10.2217\/cns-2023-0005","journal-title":"CNS Oncology"},{"key":"10235_CR39","doi-asserted-by":"publisher","first-page":"5543939","DOI":"10.1155\/2021\/5543939","volume":"2021","author":"M Tomioka","year":"2021","unstructured":"Tomioka, M., Kawase, M., Kato, D., Takai, M., Iinuma, K., Horie, K., et al. (2021). Leptomeningeal carcinomatosis in urothelial carcinoma of the urinary bladder: A report of a patient with a fulminant course who died of cancer after definitive therapies. Case Report in Urology, 2021, 5543939. https:\/\/doi.org\/10.1155\/2021\/5543939","journal-title":"Case Report in Urology"},{"issue":"6","key":"10235_CR40","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/annonc\/mdw134","volume":"27","author":"MH Geukes Foppen","year":"2016","unstructured":"Geukes Foppen, M. H., Brandsma, D., Blank, C. U., van Thienen, J. V., Haanen, J. B., & Boogerd, W. (2016). Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma. Annals of Oncology, 27(6), 1138\u20131142. https:\/\/doi.org\/10.1093\/annonc\/mdw134","journal-title":"Annals of Oncology"},{"issue":"4","key":"10235_CR41","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/nop\/npy042","volume":"6","author":"WT Arscott","year":"2019","unstructured":"Arscott, W. T., Zhu, S., Plastaras, J. P., Maity, A., Alonso-Basanta, M., & Jones, J. (2019). Acute neurologic toxicity of palliative radiotherapy for brain metastases in patients receiving immune checkpoint blockade. Neurooncology Practice, 6(4), 297\u2013304. https:\/\/doi.org\/10.1093\/nop\/npy042","journal-title":"Neurooncology Practice"},{"key":"10235_CR42","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/978-1-4615-0123-7_15","volume":"513","author":"WM Pardridge","year":"2003","unstructured":"Pardridge, W. M. (2003). Blood-brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins. Molecular and Cellular Biology of Neuroprotection in the CNS, 513, 397\u2013430. https:\/\/doi.org\/10.1007\/978-1-4615-0123-7_15","journal-title":"Molecular and Cellular Biology of Neuroprotection in the CNS"},{"issue":"11","key":"10235_CR43","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1200\/op.20.00146","volume":"16","author":"LA Huppert","year":"2020","unstructured":"Huppert, L. A., Melisko, M. E., Glastonbury, C. M., Khanafshar, E., & Daud, A. I. (2020). Treatment of metastatic melanoma with leptomeningeal disease using intrathecal immunotherapy. JCO Oncology Practice, 16(11), 757\u2013759. https:\/\/doi.org\/10.1200\/op.20.00146","journal-title":"JCO Oncology Practice"},{"key":"10235_CR44","doi-asserted-by":"publisher","unstructured":"Ensign, S. P. F., Yancey, E., Anderson, K. S., & Mrugala, M. M. (2021). Safety and feasibility of intrathecal pembrolizumab infusion in refractory triple negative breast cancer with leptomeningeal disease: a case report. Current Problems in Cancer: Case Reports, 4, 100103. https:\/\/doi.org\/10.1016\/j.cpccr.2021.100103","DOI":"10.1016\/j.cpccr.2021.100103"},{"issue":"4","key":"10235_CR45","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41591-022-02170-x","volume":"29","author":"IC Glitza Oliva","year":"2023","unstructured":"Glitza Oliva, I. C., Ferguson, S. D., Bassett, R., Jr., Foster, A. P., John, I., Hennegan, T. D., et al. (2023). Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: Phase 1 trial interim results. Nature Medicine, 29(4), 898\u2013905. https:\/\/doi.org\/10.1038\/s41591-022-02170-x","journal-title":"Nature Medicine"},{"issue":"1","key":"10235_CR46","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.2188","volume":"110","author":"O Le Tilly","year":"2021","unstructured":"Le Tilly, O., Azzopardi, N., Bonneau, C., Desvignes, C., Oberkampf, F., Ezzalfani, M., et al. (2021). Antigen mass may influence trastuzumab concentrations in cerebrospinal fluid after intrathecal administration. Clinical Pharmacology Therapeutics, 110(1), 210\u2013219. https:\/\/doi.org\/10.1002\/cpt.2188","journal-title":"Clinical Pharmacology Therapeutics"},{"issue":"5","key":"10235_CR47","first-page":"1123","volume":"52","author":"J List","year":"1992","unstructured":"List, J., Moser, R., Steuer, M., Loudon, W., Blacklock, J. B., & Grimm, E. (1992). Cytokine responses to intraventricular injection of interleukin 2 into patients with leptomeningeal carcinomatosis: Rapid induction of tumor necrosis factor \u03b1, interleukin 1\u03b2, interleukin 6, \u03b3-interferon, and soluble interleukin 2 receptor (M r 55,000 Protein). Cancer Research, 52(5), 1123\u20131128.","journal-title":"Cancer Research"},{"issue":"1","key":"10235_CR48","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3171\/jns.1988.69.1.0029","volume":"69","author":"SC Saris","year":"1988","unstructured":"Saris, S. C., Rosenberg, S. A., Friedman, R. B., Rubin, J. T., Barba, D., & Oldfield, E. H. (1988). Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier. Journal of Neurosurgery, 69(1), 29\u201334.","journal-title":"Journal of Neurosurgery"},{"issue":"3","key":"10235_CR49","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/0090-3019(91)90079-O","volume":"35","author":"J Heimans","year":"1991","unstructured":"Heimans, J., Wagstaff, J., Schreuder, W., Wolbers, J., Baars, J., Polman, C., et al. (1991). Treatment of leptomeningeal carcinomatosis with continuous intraventricular infusion of recombinant interleukin-2. Surgical Neurology, 35(3), 244\u2013247.","journal-title":"Surgical Neurology"},{"key":"10235_CR50","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1016\/S0959-8049(16)30318-5","volume":"51","author":"IC Glitza","year":"2015","unstructured":"Glitza, I. C., Rohlfs, M. L., Bassett, R., Jr., John, I., Richard, J., Iqbal, M., et al. (2015). Long-term efficacy of intrathecal interleukin-2 (IT IL2) in metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD). European Journal of Cancer, 51, S109.","journal-title":"European Journal of Cancer"},{"issue":"1","key":"10235_CR51","doi-asserted-by":"publisher","first-page":"e000283","DOI":"10.1136\/esmoopen-2017-000283","volume":"3","author":"IC Glitza","year":"2018","unstructured":"Glitza, I. C., Rohlfs, M., Guha-Thakurta, N., Bassett, R. L., Bernatchez, C., Diab, A., et al. (2018). Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open, 3(1), e000283. https:\/\/doi.org\/10.1136\/esmoopen-2017-000283","journal-title":"ESMO Open"},{"issue":"4","key":"10235_CR52","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","volume":"18","author":"ST Paijens","year":"2021","unstructured":"Paijens, S. T., Vledder, A., de Bruyn, M., & Nijman, H. W. (2021). Tumor-infiltrating lymphocytes in the immunotherapy era. Cellular & Molecular Immunology, 18(4), 842\u2013859. https:\/\/doi.org\/10.1038\/s41423-020-00565-9","journal-title":"Cellular & Molecular Immunology"},{"issue":"11","key":"10235_CR53","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1158\/2326-6066.Cir-15-0071","volume":"3","author":"IC Glitza","year":"2015","unstructured":"Glitza, I. C., Haymaker, C., Bernatchez, C., Vence, L., Rohlfs, M., Richard, J., et al. (2015). Intrathecal administration of tumor-infiltrating lymphocytes is well tolerated in a patient with leptomeningeal disease from metastatic melanoma: A case report. Cancer Immunology Research, 3(11), 1201\u20131206. https:\/\/doi.org\/10.1158\/2326-6066.Cir-15-0071","journal-title":"Cancer Immunology Research"},{"issue":"9","key":"10235_CR54","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/cas.12724","volume":"106","author":"R Ursu","year":"2015","unstructured":"Ursu, R., Taillibert, S., Banissi, C., Vicaut, E., Bailon, O., Le Rhun, E., et al. (2015). Immunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial. Cancer Science, 106(9), 1212\u20131218. https:\/\/doi.org\/10.1111\/cas.12724","journal-title":"Cancer Science"},{"issue":"10","key":"10235_CR55","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1002\/cncr.10547","volume":"94","author":"MC Chamberlain","year":"2002","unstructured":"Chamberlain, M. C. (2002). A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer, 94(10), 2675\u20132680. https:\/\/doi.org\/10.1002\/cncr.10547","journal-title":"Cancer"},{"key":"10235_CR56","unstructured":"HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases. https:\/\/classic.clinicaltrials.gov\/show\/NCT03696030.\u00a0Accessed 6\/11\/2024."},{"issue":"4","key":"10235_CR57","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Molecular Theraphy, 18(4), 843\u2013851. https:\/\/doi.org\/10.1038\/mt.2010.24","journal-title":"Molecular Theraphy"},{"key":"10235_CR58","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0297-3","volume":"5","author":"S Priceman","year":"2017","unstructured":"Priceman, S., Tilakawardane, D., Jeang, B., Murad, J., Park, A., Chang, W. C., et al. (2017). Regional intraventricular delivery of HER2-specific CAR T cells targets breast cancer metastasis to the brain. Journal for ImmunoTherapy of Cancer, 5, 95\u2013105. https:\/\/doi.org\/10.1186\/s40425-017-0297-3","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10235_CR59","unstructured":"A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV). https:\/\/classic.clinicaltrials.gov\/show\/NCT05809752.\u00a0Accessed 6\/11\/2024."},{"key":"10235_CR60","doi-asserted-by":"publisher","first-page":"A263","DOI":"10.1136\/jitc-2022-SITC2022.0248","volume":"10","author":"V Law","year":"2022","unstructured":"Law, V., Kodumudi, K., Snyder, C., Czerniecki, B., & Forsyth, P. (2022). Intrathecal delivery of dendritic cell vaccine eradicates tumor growth and protects against leptomeningeal disease re-inoculation in immunocompetent HER2(+) and triple negative breast cancer lmd xenograft models. The Journal for ImmunoTherapy of Cancer, 10, A263\u2013A263. https:\/\/doi.org\/10.1136\/jitc-2022-SITC2022.0248","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"key":"10235_CR61","doi-asserted-by":"publisher","unstructured":"Law, V., Snyder, C., Macaisa, L., Garg, S., Czerniecki, B., & Forsyth, P. A. (2023). P16.03.A development of intrathecal drug delivery platform to cure breast cancer leptomeningeal disease by dendritic cell vaccine in preclinical model. Neuro-Oncology, 25(Supplement_2), ii114-ii114, https:\/\/doi.org\/10.1093\/neuonc\/noad137.384","DOI":"10.1093\/neuonc\/noad137.384"},{"key":"10235_CR62","doi-asserted-by":"publisher","first-page":"6439614","DOI":"10.1155\/2020\/6439614","volume":"2020","author":"X Feng","year":"2020","unstructured":"Feng, X., Zhang, Z., Sun, P., Song, G., Wang, L., Sun, Z., et al. (2020). Interleukin-18 is a prognostic marker and plays a tumor suppressive role in colon cancer. Disease Markers, 2020, 6439614. https:\/\/doi.org\/10.1155\/2020\/6439614","journal-title":"Disease Markers"},{"issue":"29","key":"10235_CR63","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.2174\/092986710793176348","volume":"17","author":"S Srivastava","year":"2010","unstructured":"Srivastava, S., Salim, N., & Robertson, M. J. (2010). Interleukin-18: Biology and role in the immunotherapy of cancer. Current Medicinal Chemistry, 17(29), 3353\u20133357. https:\/\/doi.org\/10.2174\/092986710793176348","journal-title":"Current Medicinal Chemistry"},{"key":"10235_CR64","doi-asserted-by":"publisher","unstructured":"Fabbi, M., Carbotti, G., & Ferrini, S. (2015). Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP. Journal of Leukocyte Biology, 97(4), 665\u2013675. https:\/\/doi.org\/10.1189\/jlb.5RU0714-360RR","DOI":"10.1189\/jlb.5RU0714-360RR"},{"key":"10235_CR65","unstructured":"Pembrolizumab and Lenvatinib In Leptomeningeal Metastases. https:\/\/classic.clinicaltrials.gov\/show\/NCT04729348.\u00a0Accessed 6\/11\/2024."},{"key":"10235_CR66","unstructured":"Avelumab with radiotherapy in patients with leptomeningeal disease. https:\/\/classic.clinicaltrials.gov\/show\/NCT03719768.\u00a0Accessed 6\/11\/2024."},{"key":"10235_CR67","unstructured":"Clinical observation of ICI combined with recombinant human endostatin on leptomeningeal metastasis of lung cancer. https:\/\/classic.clinicaltrials.gov\/show\/NCT05385185.\u00a0Accessed 6\/11\/2024."},{"key":"10235_CR68","unstructured":"Efficacy and safety of durvalumab in non-small cell lung cancer with leptomeningeal metastasis. https:\/\/classic.clinicaltrials.gov\/show\/NCT04356222.\u00a0Accessed 6\/11\/2024."},{"key":"10235_CR69","unstructured":"Immune checkpoint inhibitors intrathecal injection in patients with leptomeningeal metastases in NSCLC. https:\/\/classic.clinicaltrials.gov\/show\/NCT06132698.\u00a0Accessed 6\/11\/2024."},{"key":"10235_CR70","unstructured":"Intrathecal Double Checkpoint Inhibition. https:\/\/classic.clinicaltrials.gov\/show\/NCT05598853.\u00a0Accessed 6\/11\/2024."},{"key":"10235_CR71","unstructured":"Intrathecal application of PD1 antibody in metastatic solid tumors with leptomeningeal disease (IT-PD1\/ NOA 26). https:\/\/classic.clinicaltrials.gov\/show\/NCT05112549.\u00a0Accessed 6\/11\/2024."},{"key":"10235_CR72","unstructured":"Lymphodepletion plus adoptive cell transfer with or without dendritic cell immunization in patients with metastatic melanoma. https:\/\/classic.clinicaltrials.gov\/show\/NCT00338377.\u00a0Accessed 6\/11\/2024."},{"key":"10235_CR73","unstructured":"BATs in patients with breast cancer and leptomeningeal metastases. https:\/\/classic.clinicaltrials.gov\/show\/NCT03661424.\u00a0Accessed 6\/11\/2024."},{"key":"10235_CR74","unstructured":"177Lu-DTPA-Omburtamab radioimmunotherapy for leptomeningeal metastasis from solid tumors (Breast, NSCLC, Malignant Melanoma). https:\/\/classic.clinicaltrials.gov\/show\/NCT04315246.\u00a0Accessed 6\/11\/2024."},{"issue":"14","key":"10235_CR75","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1158\/1078-0432.Ccr-21-1694","volume":"27","author":"I Smalley","year":"2021","unstructured":"Smalley, I., Chen, Z., Phadke, M., Li, J., Yu, X., Wyatt, C., et al. (2021). Single-cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases. Clinical Cancer Research, 27(14), 4109\u20134125. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-1694","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10235_CR76","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41523-023-00526-1","volume":"9","author":"KW Im","year":"2023","unstructured":"Im, K. W., Huppert, L. A., Malevanchik, L., Rugo, H. S., Combes, A. J., Campbell, M. J., et al. (2023). High-dimensional immune cell profiling of cerebrospinal fluid from patients with metastatic breast cancer and leptomeningeal disease. npj Breast Cancer, 9(1), 22. https:\/\/doi.org\/10.1038\/s41523-023-00526-1","journal-title":"npj Breast Cancer"},{"issue":"39","key":"10235_CR77","doi-asserted-by":"publisher","first-page":"15016","DOI":"10.1073\/pnas.0801497105","volume":"105","author":"SD Blackburn","year":"2008","unstructured":"Blackburn, S. D., Shin, H., Freeman, G. J., & Wherry, E. J. (2008). Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci U S A, 105(39), 15016\u201315021. https:\/\/doi.org\/10.1073\/pnas.0801497105","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10235_CR78","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/2159-8290.CD-17-1033","volume":"8","author":"L Chen","year":"2018","unstructured":"Chen, L., Diao, L., Yang, Y., Yi, X., Rodriguez, B. L., Li, Y., et al. (2018). CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1\/PD-L1 blockade. Cancer Discovery, 8(9), 1156\u20131175. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1033","journal-title":"Cancer Discovery"},{"issue":"8","key":"10235_CR79","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.3390\/cancers13081946","volume":"13","author":"E Cendrowicz","year":"2021","unstructured":"Cendrowicz, E., Sas, Z., Bremer, E., & Rygiel, T. P. (2021). The role of macrophages in cancer development and therapy. Cancers (Basel), 13(8), 1946. https:\/\/doi.org\/10.3390\/cancers13081946","journal-title":"Cancers (Basel)"},{"issue":"7769","key":"10235_CR80","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","volume":"572","author":"AA Barkal","year":"2019","unstructured":"Barkal, A. A., Brewer, R. E., Markovic, M., Kowarsky, M., Barkal, S. A., Zaro, B. W., et al. (2019). CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature, 572(7769), 392\u2013396. https:\/\/doi.org\/10.1038\/s41586-019-1456-0","journal-title":"Nature"},{"issue":"10","key":"10235_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e20507","volume":"9","author":"A Khalaji","year":"2023","unstructured":"Khalaji, A., Yancheshmeh, F. B., Farham, F., Khorram, A., Sheshbolouki, S., Zokaei, M., et al. (2023). Don\u2019t eat me\/eat me signals as a novel strategy in cancer immunotherapy. Heliyon, 9(10), e20507. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e20507","journal-title":"Heliyon"},{"issue":"1","key":"10235_CR82","doi-asserted-by":"publisher","first-page":"2163781","DOI":"10.1080\/2162402X.2022.2163781","volume":"12","author":"T Xu","year":"2023","unstructured":"Xu, T., Karschnia, P., Cadilha, B. L., Dede, S., Lorenz, M., Seewaldt, N., et al. (2023). In vivo dynamics and anti-tumor effects of EpCAM-directed CAR T-cells against brain metastases from lung cancer. OncoImmunology, 12(1), 2163781. https:\/\/doi.org\/10.1080\/2162402X.2022.2163781","journal-title":"OncoImmunology"},{"issue":"3","key":"10235_CR83","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1158\/1078-0432.Ccr-23-1735","volume":"30","author":"AM Kieliszek","year":"2024","unstructured":"Kieliszek, A. M., Mobilio, D., Upreti, D., Bloemberg, D., Escudero, L., Kwiecien, J. M., et al. (2024). Intratumoral delivery of chimeric antigen receptor T cells targeting CD133 effectively treats brain metastases. Clinical Cancer Research, 30(3), 554\u2013563. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-1735","journal-title":"Clinical Cancer Research"},{"key":"10235_CR84","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3389\/fimmu.2017.01850","volume":"8","author":"HR Mirzaei","year":"2017","unstructured":"Mirzaei, H. R., Rodriguez, A., Shepphird, J., Brown, C. E., & Badie, B. (2017). Chimeric antigen receptors T cell therapy in solid tumor: Challenges and clinical applications. Frontiers in Immunology, 8, 1850. https:\/\/doi.org\/10.3389\/fimmu.2017.01850","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"10235_CR85","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris, E. C., Neelapu, S. S., Giavridis, T., & Sadelain, M. (2022). Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nature Reviews Immunology, 22(2), 85\u201396. https:\/\/doi.org\/10.1038\/s41577-021-00547-6","journal-title":"Nature Reviews Immunology"},{"issue":"1","key":"10235_CR86","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/imr.13231","volume":"320","author":"CM Snyder","year":"2023","unstructured":"Snyder, C. M., & Gill, S. I. (2023). Good CARMA: Turning bad tumor-resident myeloid cells good with chimeric antigen receptor macrophages. Immunological Reviews, 320(1), 236\u2013249. https:\/\/doi.org\/10.1111\/imr.13231","journal-title":"Immunological Reviews"},{"issue":"1","key":"10235_CR87","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12951-023-01810-9","volume":"21","author":"L Gao","year":"2023","unstructured":"Gao, L., Shi, C., Yang, Z., Jing, W., Han, M., Zhang, J., et al. (2023). Convection-enhanced delivery of nanoencapsulated gene locoregionally yielding ErbB2\/Her2-specific CAR-macrophages for brainstem glioma immunotherapy. Journal of Nanobiotechnology, 21(1), 56. https:\/\/doi.org\/10.1186\/s12951-023-01810-9","journal-title":"Journal of Nanobiotechnology"},{"issue":"8","key":"10235_CR88","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky, M., Ruella, M., Shestova, O., Lu, X. M., Best, A., Zeeman, M., et al. (2020). Human chimeric antigen receptor macrophages for cancer immunotherapy. Nature Biotechnology, 38(8), 947\u2013953. https:\/\/doi.org\/10.1038\/s41587-020-0462-y","journal-title":"Nature Biotechnology"},{"issue":"1","key":"10235_CR89","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12967-023-04061-2","volume":"21","author":"Y Huo","year":"2023","unstructured":"Huo, Y., Zhang, H., Sa, L., Zheng, W., He, Y., Lyu, H., et al. (2023). M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors. Journal of Translational Medicine, 21(1), 225. https:\/\/doi.org\/10.1186\/s12967-023-04061-2","journal-title":"Journal of Translational Medicine"},{"key":"10235_CR90","doi-asserted-by":"publisher","unstructured":"Wu, S.-Y., Wu, K., Tyagi, A., Xing, F., Zhao, D., Deshpande, R. P., et al. (2022). Abstract 6153: MyD88-mediated chimeric antigen receptor macrophage suppresses brain metastasis by target-specific phagocytosis and bystander effect through TNF-\u03b1. Cancer Research, 82(12_Supplement), 6153-6153, https:\/\/doi.org\/10.1158\/1538-7445.Am2022-6153","DOI":"10.1158\/1538-7445.Am2022-6153"},{"key":"10235_CR91","unstructured":"Human HER2-targeted macrophages therapy for HER2-positive advanced gastric cancer with peritoneal metastases. https:\/\/classic.clinicaltrials.gov\/show\/NCT06224738.\u00a0Accessed 6\/11\/2024."},{"key":"10235_CR92","unstructured":"CAR-macrophages for the treatment of HER2 overexpressing solid tumors. https:\/\/classic.clinicaltrials.gov\/show\/NCT04660929.\u00a0Accessed 6\/11\/2024."}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-024-10235-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-024-10235-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-024-10235-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T02:58:45Z","timestamp":1743303525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-024-10235-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10235"],"URL":"https:\/\/doi.org\/10.1007\/s10555-024-10235-1","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]},"assertion":[{"value":"27 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Emily Douglas serves on the advisory board of Novartis","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"10"}}